Niacin for primary and secondary prevention of cardiovascular events

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:To assess benefits and harms of combination therapy including niacin and other lipid-modifying drugs versus other lipid-modifying drugs alone or niacin versus placebo or usual care in patients with or at risk of CVD disease, in terms of mortality and CVD events.